Fig 3.

Time to first progression or death was plotted by mutation position along either the BRCA1 or BRCA2 gene, or by mutation type. Progression is only plotted for patients whose disease progressed by the censoring date; time to death was only plotted for those patients who died as a result of disease-related causes before the censoring date. The line represents the median. Thirty-five of the mutation-positive patients (24.8%) had remained progression free at the time of data censoring for this study. (A) Time to first progression in patients with a BRCA1 mutation who were optimally debulked (nil or ≤ 1 cm residual disease; gold plus symbols) or suboptimally debulked (blue) at time of primary surgery. (B) Time to death in BRCA1 mutation–positive cases who were optimally (gold) or suboptimally (blue) debulked at time of primary surgery. Deaths as a result of disease-related causes (n = 45; plotted); deaths as a result of nondisease-related causes (n = 3; not plotted). (C) Time to first progression in patients with a BRCA2 mutation who were optimally (gold) or suboptimally (blue) debulked at time of primary surgery. (D) Time to death in BRCA2 mutation–positive women who were optimally (gold) or suboptimally (blue) debulked at time of primary surgery. Deaths as a result of disease-related causes (n = 26; plotted); deaths as a result of nondisease-related causes (n = 2; not plotted). (E) Time to first progression by mutation type. A deletion or insertion was considered multiple base if at least two base pairs were involved. (F) Time to death by mutation type. Deaths as a result of disease-related causes (n = 71; plotted); deaths as a result of nondisease-related causes (n = 5; not plotted). A deletion or insertion was considered multiple base if at least two base pairs were involved. HGVS, Human Genome Variation Society.